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Some countries’ pharmaceutical benefits programs such as Australia, Canada, or
U.S. listed DEs for pancreatic insufficiency due to chronic pancreatitis, carcinoma
of the pancreas, or cystic fibrosis, however, those reimbursed by Taiwan NHI had
broader scope of indications. In addition to more medical orders prescribed by
varied health care specialties, we observed the expenditure increased by approxi-
mately two times over the past 10 years.
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OBJECTIVES:Knowledge and practice of disposal of date expired and unused drugs
among college students and people having a health science background and to find
the most widely used method of drug disposal for the expired drugs in the study
group.METHODS:Apilot study questionnairewas prepared and a surveywas done
among students with Health Science background to understand the appropriate-
ness of content. Further 500University students andpeople having ahealth science
background were interviewed personally using the validated questionnaire pre-
pared. Results were presented percentage responses and interpretation of the re-
sults helped in the derivation of the final conclusion. RESULTS:When asked about
the awareness of the existing guidelines for the safe disposal of drugs in various
countries 56% of the respondents knew about it while 44%were unaware. A total of
52.2% of the respondents agreed that the wrong drug disposal methods can lead to
adverse environmental effects while 25.6% strongly agreed to it. A mere 4.8% dis-
agreed to the statementwhile another 17.4% somewhat agreed to it; 56.8% strongly
agreed to the fact that there was a need of a drug take back system in their place of
residence. A total of 57.2% opined that there was a need of public awareness pro-
grams to increase the awareness about drug disposal in the general public. A ma-
jority 91.2% of the respondents admitted that they simply throw the expired drugs
into the dustbins. 46.8% of the people said there was no work being done in this
context by any organization. CONCLUSIONS: The study clearly indicates lack of
awareness and good practices of date expired drugs among surveyed population.
There is a need to create awareness regarding disposal of drugs among the popu-
lation which should be done either by the government or any organization.
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ANALYZING THE UTILITIES OF FLUOROQUINOLONES AT A REGIONAL
TEACHING HOSPITAL OF SOUTHERN TAIWAN
Lin PT
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OBJECTIVES: Adequate use of antimicrobial agent is critical issue in hospital. It
would enlarge the burden, for instance increase medical expenditure and antimi-
crobial resistance rate, if misuse. To evaluate the annual use of the third line
antibiotic agents - fluoroquinolones, including ciprofloxacin, moxifloxacin and
levofloxain, and that could be took a reference to manage the use in a regional
teaching hospital.METHODS: The data, including patient-days and the consump-
tion quantity of ciprofloxacin, moxifloxacin and levofloxain, was extracted
monthly from Hospital Information System of a regional teaching hospital from
January 2010 to December 2011. Consumption quantity was transferred to
“1000DDD /patient-days”. Data management and analysis was performed using
student t test. RESULTS:Number of 1000DDD /patient-days in all fluoroquinolones
were 202.47 in 2010, 202.47 in 2022 and there was no significantly difference
(p0.067). Number of 1000DDD /patient-days in ciprofloxacin significantly de-
creased (p 0.0023) in 2011(1000DDD /patient-days 127.35) comparing with 2010
does (1000DDD /patient-days 181.69). Number of 1000DDD /patient-days inmoxi-
floxacin were 38.95 in 2010 and 48.08 in 2011. In the aspect of levofloxacin, number
of 1000DDDwere 25.46 in 2010 and 27.03 in 2011. The number of 1000DDD /patient-
days in Moxifloxacin and levofloxacin both were no significantly difference be-
tween 2011 and 2010. CONCLUSIONS: The fluoroquinolones consumption de-
creased especially on ciprofloxacin, but the levofloxacin and moxifloxacin mild
increased. Although no significantly difference on the amount of all fluoroquino-
lones between 2010 and 2011may be good and stand for well control. But extenting
the study to the outcomes of infection control and the association of the culture
results would be more objective.
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OBJECTIVES: To identify the nature and frequency of DRPs (drug interaction and
irrational dose), and their impacts on length of stay (LOS) of patients with chronic
kidney disease (CKD) stage 4 and 5 hospitalized in Haji AdamMalik (HAM) Hospital,
Indonesia. METHODS: This retrospective cohort study was conducted on 80 pa-
tients based on JAMKESMAS database for 6-month period (October 2009 - March
2010). Inclusion criteria were patients administered antibiotics and GFR of 30
mL/min/1.73 m2. Exclusion criteria were patients under 18 years old, patients with
cancer, and patient with Human Immunodeficiency Virus (HIV). Data collected
include type of drugs administered, laboratory tests, and clinical outcomes. Iden-
tification of drug interaction and analysis of antibiotics dose rationality were per-
formed using Stockley’s drug interactions, Medlines, and Handbook of Clinical
Drug Data. The impacts of DRPs on LOS were performed by multiple linear regres-
sion analysis. RESULTS: Of the sample, male was 66% and female was 34%; CKD
stage 4 was 17% and CKD stage 5 was 83%. Most drug interactions were between
NSAIDs and ACE inhibitor, ranitidine and furosemide, ranitidine and ciprofloxacin,
metoclopramide and NSAIDs, dexamethasone and furosemide, NSAIDs and furo-
semide.Mean value of drug interactionwas 1 1.31.Most frequent irrational doses
of antibiotics involved ceftriaxone, ceftazidime, cefadroxyl, ciprofloxacin, and
amoxicillin. Mean value of irrational doses was 0.43  0.67. Means of LOS was
6.645.76.Multiple linear equation obtained: y 3.91 2.16x1 0.97x2; y LOS; x1
 drug interaction; x2 irrational dose of antibiotics. CONCLUSIONS: This finding
must be highlighted and considered to optimize treatment of CKD. Impact of drug
interaction on LOS of CKD patients was higher compared to that of irrational dose
of antibiotics.
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OBJECTIVES: Although most of the medications containing herbal extracts have
been used in the treatment of diseases for many years, the evidence on the clinical
efficacy and safety are still in controversy. It is necessary to conduct an evaluation
on these products.METHODS: First, we defined the medications containing herbal
extracts in this study, aswell as identified the items reimbursed inNational Health
Insurance. In the next step, we analyzed the 2001-2007 National Health Insurance
Research Database (NHIRD) to find themost frequently used items in the category.
Silymarin was identified as the most used during 2001-2007. We conducted the
literature search and review on the clinical effectiveness of the ingridient.
RESULTS: In this review, we summarized the reports published by the literature.
These reports had systematically reviewed on the topic of the effectiveness of
silymarin in patients with alcoholic and /or hepatitis B or C liver diseases. In the
report by The Cochrane Collaboration - a total of thirteen randomized trials as-
sessed silymarin in patients with alcoholic and /or hepatitis B or C liver diseases
were included in the meta-analysis. Results from these trials showed a significant
effect of silymarin on liver-related mortality (RR 0.50, 95% CI 0.29 - 0.88), but no
significant effects could be demonstrated if the analysis were restricted on only
high quality trials (RR 0.57, 95% CI 0.28 - 1.19). For the resource utilization of sily-
marin, we found that the total claims on silymarin increased 59.83% fromyear 2001
to 2007. CONCLUSIONS: As mentioned above, the effectiveness of silymarin in
patients with liver disease has not been established. Further studies on mecha-
nisms of action, as well as related well-designed clinical trials are needed.
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IS THERE A DIFFERENCE IN PRESCRIPTION MEDICATION UTILIZATION
BETWEEN AGED ADULTS WITH AND WITHOUT DISABILITY IN THE UNITED
STATES?
Liu CM, Batra P, Erickson S, Farris K
The University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To quantify the association between disability and prescriptionmed-
ication use among older adults. Individuals with disability may consume more or
varying types of prescription medication, thereby requiring special services.
METHODS: Data from the nationally-representative Health and Retirement Study
2006 and the Prescription Drug Study 2007 in the United States were used to exam-
ine associations between disability and prescription medication use among 2,755
adults. The dependent variable, disability versus no disability, was determined
based on responses to questions assessing functional, mobility, and cognitive sta-
tus. Subjects responding affirmatively to one of these types of disabilities were
classified as disabled. Chi-square tests assessed the dependent categorical vari-
ables by disability. Negative binomial regressions were used to examine the rela-
tionship between disability and prescriptionmedication use, controlling for acces-
sibility, affordability, beliefs in medication, health conditions and socio-
demographic variables. RESULTS: Of the 2,755 subjects, 70.8% were classified as
disabled. Female, older, non-white, widowed, less educated, living in rural area,
lower income, having three chronic diseases, poor health status, no alcohol or
smoking habits, hardly exercise, taking prescription drugs regularly, and consult-
ing with medical doctors more were all statistically significant variables indicative
of greater risk of disability (P0.0001). Subjects classified as disabled [IRR1.09 (95%
CI, 1.03-1.15)], with three or more chronic conditions [IRR2.08 (95% CI, 1.93-2.35)],
not exercising [IRR1.08 (95% CI, 1.04-1.10)], taking medications regularly
[IRR1.85 (95% CI, 1.51-2.27)] and sevenmore times doctor visits [IRR1.46 (95% CI,
1.36-1.57)] had a greater incidence of prescription medication uses. Subjects with
lower income [IRR0.99 (95% CI, 0.99-0.99)], no alcohol or smoking habits [IRR0.93
(95% CI, 0.88-0.98)] had a lower incidence likelihood of prescription medication
uses. CONCLUSIONS:Disability was a statistically significant predictor of prescrip-
tion medication use. Further research is necessary to examine the associations
between specific disability types and medications use.
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COMPARING ORAL 5-AMINOSALICYLIC ACID TREATMENT PERSISTENCE AND
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OBJECTIVES: Compare oral 5-aminosalicylic acid (5-ASA) treatment persistence
and adherence in patients with mild/moderate ulcerative colitis (UC). METHODS:
IMS LifeLink™Health Plan claims datawere analyzed to identify patients18 years
with 1 UC diagnosis (ICD-9-CM: 556.x) and had 1 prescription for 5-ASA (sul-
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fasalazine, Multi-Matrix System mesalamine [MMX], balsalazide disodium, mesa-
lamine delayed release [MDR]) during 2007-2011. Patients were continuously en-
rolled in the 6-month pre- and 12-month post-initiation period. 5-ASA treatment
persistence and adherence according to the initial prescription filled (index medi-
cation) were compared. Persistence was defined as the duration between initiation
and discontinuation of therapy with a permissible gap 60 days, and analyzed
using Kaplan-Meier survival analysis. Persistence rates at month 12 were calcu-
lated. Adherence was measured by medication possession ratio (MPR) for index
drug, and proportion of days covered (PDC) for any 5-ASA. Analysis of covariance
was used to compare MPR and PDC across index medication. Covariates included
age, gender, insurance, residential region, comorbidities at index date, and use of
immunosuppressive/biologic agents, rectal form of 5-ASA and access to specialist
care post 12-month index date. RESULTS: A total of 5245 patients met selection
criteria, 59% were on MDR, 17% MMX, 13% sulfasalazine, and 11% balsalazide. The
median persistence days ranged from 151 [sulfasalazine] to 221 [MMX] days,
P0.001). Persistence rates at month 12 was highest for MMX (28%) compared to
other 5-ASAs (24% MDR, 23% balsalazide, and 20% sulfasalazine, respectively,
logrank P0.001). Mean adjusted MPR/PDC  standard error was significantly
higher in the patients on MMX (0.480.02/0.530.02) than that of patients on other
5-ASAs (0.430.01/0.500.01 [MDR], 0.430.02/0.490.02 [balsalazide], and
0.390.02/0.470.02 [sulfasalazine], P0.01/P0.04). CONCLUSIONS: Patients on
once-daily MMX were significantly more persistent and adherent with UC treat-
ment than those on other 5-ASA index drugs although persistence and adherence
with oral 5-ASAs in UC patients were suboptimal.
PHP37
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INHIBITORS TO ANGIOTENSIN RECEPTOR BLOCKERS IN TAIWAN
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OBJECTIVES: Our previous study suggested that Taiwan’s drug price adjustments
result in prescription switching from cheaper angiotensin-converting enzyme in-
hibitors (ACEIs) to expensive angiotensin receptor blockers (ARBs), demonstrated
by a macro level data that showed a decrease use in ACEIs and an increase use in
ARBs after policy implementation and by a long-term increasing trend observed in
annual prevalent ARB users that exceeded the cumulative incident ARB users. This
study uses individual patient level data to examine the proportions of prescription
switching from ACEIs to ARBs among the prevalent ARB users. METHODS: We
identified 82,447 patients treated with ARBs between Feb 1998 and Dec 2008 from
Taiwan’s Longitudinal Health Insurance Database (LHID2005). We examined the
monthly prevalent users of ARBs (from 2/1998 - 12/2008), the incident users of ARBs
(who receive ARBs first time in a givenmonth fromFeb 1998 to Dec 2008 and did not
receive ACEIs or ARBs in the preceding months from 1997 to 2008), and the ACEIs-
to-ARBs switchers (who used ARBs in a given month and used ACEIs or both drugs
[ACEIs in combinationwith ARBs] in lastmonth during 2/1998 - 12/2008). RESULTS:
The number of monthly prevalent ARB users increased from 4 to 32,292 from Fe-
burary 1998 to December 2008. The growth of ARB prevalent users was mainly
contributed by the incident ARB users and the ACEIs-to-ARBs switchers. The num-
ber of monthly incident ARB users increased from 2 to 562 and that of monthly
ACEIs-to-ARBs switchers increased from 1 to 477 from February 1998 to December
2008. The number of ACEIs-to-ARBs switchers exceeds that of incident ARB users
(averagemonthly ratio of the former to the latter is 1.25). CONCLUSIONS: Prescrip-
tion switching from cheaper ACEIs to expensive ARBs based on individual patient
level data is evident. Policy makers should be aware of this problem.
HEALTH CARE USE & POLICY STUDIES - Equity And Access
PHP38
PERSISTENT RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE UTILIZATION
– EVIDENCE FROM NATIONAL HEALTH INTERVIEW SURVEY
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OBJECTIVES: To evaluate the extent towhich racial and ethnic disparities in health
care utilization persist longitudinally. METHODS: We analyzed data from 2008 to
2010 National Health Interview Survey (NHIS) in the United States to examine
insurance status and utilization of health care based on race/ethnicity (non-His-
panic White, Hispanic White, Black, Asian, and others). We used two outcome
measures to define utilization of health care: at least one physician visit every two
weeks, and the average number of physician visits every twoweeks.We performed
multiple linear regression and logistic regression with sampling weight adjust-
ments for data analysis, stratified by dichotomous insurance status. Survey re-
spondents with private or public insurance or both were considered insured; oth-
erwise uninsured. All analyses were adjusted for age, education, gender, income-
to-poverty ratio, self-reported health status, and activity limitation. RESULTS:
Overall, insured rates decreased from 2008 to 2010 and the decreasing rate was
significantly associated with race/ethnicity (p0.01). Particularly, Asian had a
faster decreasing rate comparedwith non-Hispanicwhite (p0.05). The probability
of having at least one physician visit every two weeks for insured adults slightly
increased during 2008 and 2010, and was not significantly associated with race/
ethnicity. However, insured HispanicWhite and Asian Americans were still signif-
icantly less likely to have at least one physician visit every two weeks in compar-
ison to non-HispanicWhite (p0.05). The average number of physician visits every
two weeks for insured adults was significantly associated with year and race/eth-
nicity (p0.01). Both outcome measures did not significantly change from 2008 to
2010 for uninsured adults. CONCLUSIONS: Reducing racial and ethnic disparities is
an important priority in the United States. The results from NHIS show such dis-
parities in health care utilization persist regardless of insurance status. More stud-
ies are needed to identify other factors associated with such disparities.
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PRESCRIPTION FILLING ON OUTPATIENT HEALTH CARE DEPARTMENTS: AN
INDONESIA FAMILY LIFE SURVEY (IFLS) YEAR 2007 – 2008 BASED STUDY
Himawan R
Ministry of Health, South Jakarta, DKI Jakarta, Indonesia
OBJECTIVES: To identify the rate of patient’s prescription filling in outpatient
health care departments in Indonesia, and to examine its related factor.
METHODS: Secondary data from the 4thWave Indonesia Family Life Survey (IFLS,
RAND Corp.) were used to obtain the Indonesia patients socio-economic charac-
teristics including their behavior on filling prescription in outpatient health care
departments. Factors related to prescription filling were identified from similar
studies such as educational level, economic status, geographical status (urban-
village, mainland-based), health insurance coverage, catastrophic health care
costs, satisfaction from health care received, andmorbidity (days of illness, illness
condition). Statistical analyses such as univariate, bivariate, andmultivariate anal-
yses were performed in a cross-sectional study to identify and to examine the
relationship between those factors with prescription filling rate. Meanwhile, inter-
action test also performed among variables in the multivariate model. RESULTS:
Six hundred forty-one respondent data were eligible and used for analysis pur-
poses. Results showed that 85,49% patients from outpatient health care depart-
ment filled their prescriptions. Bivariate analysis showed that factors related to the
prescription filling rate were educational level (p0,031), economic status
(p0,085), geographical status (p0,016 for urban-village, p0,000 for mainland-
based), and catastrophic outpatient health care costs (p0,060). Meanwhile, mul-
tivariate analyses showed that only geographical status (p 0,019 for urban-village)
was significant. In terms of geographical status, patients who lived in Java Island
had 1,6 times greater possibilities in prescription filling compared to patients who
lived in other islands. No interaction identified between variables in the last mul-
tivariate model. CONCLUSIONS: Prescription filling in the outpatient health care
department can be considered not optimum. Policy to enhance prescription filling
in outpatient health care department should put an emphasize on geographical
conditions of Indonesia which consists of thousand islands.
PHP40
EQUITY IN PHARMACEUTICAL PRICING AND REIMBURSEMENT: CROSSING THE
INCOME DIVIDE IN ASIA PACIFIC
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OBJECTIVES: Providers of a new technology are increasingly obliged to give gov-
ernments an insight into related costs and benefits, and its value for money. This
necessitates the use of cost-effectiveness (CEA) and cost-utility data. A good health
policy, however,must not only aim to be efficient but should also guarantee equity.
METHODS: An analytic model has been developed to assess the ability to pay for
128 countries. The method introduces proportionality into pricing and reimburse-
ment decisions across and within Asia Pacific countries by taking into account
purchasing power paritymeasured at either the national or household level. Value-
based pricing techniques are used in combination with national income parame-
ters as defined in the Human Development Index together with health system
variables. The resulting non-linear equity curve is a graphic representation of a
price index calculated based on a country’s national income. The ratio of wealth
inversely reflects the theoretical discount rate that can be applied to each country
compared to a high income reference country. The steepest discounts are reserved
for the poorest countries, while for middle and high-income countries discounts
will decrease as the country’s wealth increases. RESULTS: The degree to which
‘equitable pricing’ offers a sustainable solution to the problem of access to medi-
cines depends on: the economic development status of a country, the value of a
particular medicine to its therapeutic class and the incidence of the disease, and
the extent to which segmentation can be applied. CONCLUSIONS: Equitable, dif-
ferentiated pricing can improve access to and affordability of medicines, particu-
larly in low- and middle-income countries. The method is relevant for the Asia
Pacific region confronted with disparity in the ability-to-pay (ATP) between coun-
tries, and between different population segments in the same country.
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RISK MANAGEMENT IN IRANIAN PHARMACEUTICAL COMPANIES TO ENSURE
ACCESSIBILITY AND QUALITY OF MEDICINES
Jaberidoost M, Abdollahiasl A, Farshchi A, Dinarvand R
Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES: Medicine Quality and accessibility are two of the main objectives of
health care systems. Pharmaceutical manufacturers have an important role to
meet these goals. But they are facedwith complicated environment and uncertain-
tieswhichcan affect ontheir performance and also accessibility andquality ofmed-
icines. Risk management is a new approach to assess and overcome these uncer-
tainties. In this study we have tried to identify, assess and make mitigation
strategies to manage risks which can affect on accessibility and quality of medi-
cines in three Iranian pharmaceutical companies.METHODS: First: The literatures
were reviewed for identification and categorization of potential risks. Second, a
semi-structured questionnaire was developed to get expert opinions about priori-
tization of risks andmitigations strategies. Third: the questionnaires were filled by
face to face interviewwith executive managers of three companies. RESULTS: Five
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